ASAmareshwar T. K. Singh

Amareshwar T. K. Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amareshwar T. K. Singh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin N. Ho

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.

    2 shared publications
  • Claire M. Pfeffer

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.

    2 shared publications
  • Claire M. Pfeffer

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI 53140, USA

    1 shared publication
  • Elizabeth S. Wenzel

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.

    1 shared publication
  • Manar Mohammad

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.

    1 shared publication
  • Richard G Stauffer

    Department of Biology, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A.

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Apoptosis: A Target for Anticancer Therapy

    by Claire M. Pfeffer, Amareshwar T. K. Singh

    Apoptosis, the cell’s natural mechanism for death, is a promising target for anticancer therapy. Both the intrinsic and extrinsic pathways use caspases to carry out apoptosis through the cleavage of hundreds of proteins. In cancer, the apoptotic pathway is typically inhibited through a wide variety of means including overexpression of antiapoptotic proteins and under-expression of proapoptotic proteins. Many of these changes cause intrinsic resistance to the most common anticancer therapy, chemotherapy. Promising new anticancer therapies are plant-derived compounds that exhibit anticancer activity through activating the apoptotic pathway.


  • Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer

    by Elizabeth S. Wenzel, Amareshwar T. K. Singh

    The cell cycle is a complex sequence of events through which a cell duplicates its contents and divides, and involves many regulatory proteins for proper cellular reproduction, including cyclin proteins and cyclin-dependent kinases, oncogenes and tumor-suppressor genes, and mitotic checkpoint proteins. Mutations of any of these regulatory mechanisms can lead to reproduction of cells carrying genetic mutations or abnormal numbers of chromosomes, resulting in genomic instability. Chromosomal instability, contributing to genomic instability, refers to abnormalities in the number of chromosomes, and leads to aneuploidy. The role of aneuploidy in cancer cell development is often disputed, as conflicting hypotheses and research make it unclear as to whether aneuploidy is a cause or consequence of cancer. Here, we present an overview of the importance of cell-cycle checkpoint regulation and chromosomal instability in the development of cancer, and discuss evidence for conflicting arguments for the role of aneuploidy in cancer, leading us to conclude that further investigation of this role would benefit our understanding of cancer development.


  • Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment

    by Benjamin N. Ho, Claire M. Pfeffer, Amareshwar T.K. Singh

    The emerging field of nanotechnology meets the demands for innovative approaches in the diagnosis and treatment of cancer. The nanoparticles are biocompatible and biodegradable and are made of a core, a particle that acts as a carrier, and one or more functional groups on the core which target specific sites. Nanotech in drug delivery includes nanodisks, High Density Lipoprotein nanostructures, liposomes, and gold nanoparticles. The fundamental advantages of nanoparticles are: improved delivery of water-insoluble drugs, targeted delivery, co-delivery of two or more drugs for combination therapy, and visualization of the drug delivery site by combining imaging system and a therapeutic drug. One of the potential applications of nanotechnology is in the treatment of cancer. Conventional methods for cancer treatments have included chemotherapy, surgery, or radiation. Early recognition and treatment of cancer with these approaches is still challenging. Innovative technologies are needed to overcome multidrug resistance, and increase drug localization and efficacy. Application of nanotechnology to cancer biology has brought in a new hope for developing treatment strategies on cancer. In this study, we present a review on the recent advances in nanotechnology-based approaches in cancer treatment.


  • Open Access

    The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2

    by Claire M. Pfeffer, Benjamin N. Ho, Amareshwar T.K. Singh

    BRCA1 and BRCA2 are both tumor suppressors whose mutations are the cause of most hereditary breast cancers. Both genes are highly involved in ensuring genome stability. BRCA1 homologs are found in the plant and animal kingdoms while BRCA2 homologs are additionally found in the fungi kingdom. The initial origin of both genes remains unknown, however it is expected that the common ancestors originated around 1.6 billion years ago prior to the kingdoms diverging. There has been a great amount of divergence between homologs that is not observed in other tumor suppressors with only functionally important domains conserved. This divergence continues today with evidence of primate BRCA1/2 evolution. Cancer-associated mutations have been found to occur at conserved sites, indicating that conserved sites are important for function. In this study, we present a review on the phylogenesis of BRCA1 and BRCA2.


    • 1 December 2015
      • Vol. 35  (12) , 6425-9

    Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen.

    by Richard G Stauffer, Manar Mohammad, Amareshwar T K Singh

    Mantle cell lymphoma (MCL), a B-cell lymphoma, pursues a relatively aggressive course, is resistant to long-term remission, and is associated with a poor prognosis. There is a pressing need for innovative treatment approaches against MCL. One such approach is targeted delivery of cytotoxic drugs to MCL cells. In the current investigation, we pursued a strategy to employ retinoid-based or curcumin-based nanoscale delivery particles, called nanodisks (NDs), for targeted drug delivery to MCL cells (Granta), and human follicular lymphoma (HF-1) cells. The cells were incubated with NDs made of CD20 single-chain variable antibody fragment (scFv)/apolipoprotein A-1 fusion protein, and loaded with either all-trans retinoic acid (ATRA) or curcumin, and cell apoptosis was measured using flow cytometry. At 10 μM, curcumin-ND induced cell death more effectively than ATRA-ND. Combination of curcumin-ND and ATRA-ND significantly enhanced the biological activity of these drugs against lymphoma cells compared to individual treatments.